DFB Pharmaceuticals Inc.
3909 Hulen St.
With years of experience in the pharmaceutical industry, Paul Dorman used that expertise in an entrepreneurial venture to develop new life-saving drugs.
Dorman purchased majority ownership of DPT Laboratories in San Antonio from Alcon Laboratories of Fort Worth in 1990. Under his leadership as chairman of the board and CEO, he expanded DPT into DFB, a holding company that sells services and its own drug brands globally through its operating centers in Texas New Jersey, German and Canada.
The company has grown from 150 employees and $18 million in sales in 1990 to about a workforce of more than 1,500 and annual sales of about $400 million.
DFB’s portfolio of health care companies included Healthpoint Biotheraputics, which advanced research in the use of live human cells in regenerate skin growth and heal open wounds.
Healthpoint was sold to Smith & Nephew in 2012 to establish a global medical technology firm dedicated to bioactive wound care treatment.
“Healthpoint and Smith & Nephew have much in common – our commitment to innovation, the desire to serve healthcare professionals and a fundamental dedication to improving the quality of life for patients,” Dorman said in a statement at the time of the sale.
DFB has sold other affiliated companies as well but continues to operate Phyton Biotech, a pioneer in the development and manufacture of plant-based molecules for the treatment of cancer and other diseases. If successful in clinic trials, the protocol could revolutionize the traditional method of chemotherapy treatment.
Dorman, who is continually on the lookout for new business opportunities, had sharpened his entrepreneurial instincts before buying and transforming DPT Laboratories. He previously resuscitated three industrial distribution companies from bankruptcy and sold them.
Prior to that, he held management positions with pharmaceutical leaders Johnson & Johnson and Baxter International.
Dorman told the Fort Worth Business Press that successful entrepreneurship is the result of instinct and conservative financial decision-making.
“Many business will either become over leveraged or sell equity to support growth and we’ve never had to do that,” he said. “We’ve been very conservative and that’s been to our benefit.”
– Marice Richter